Bifidobacterium breve trials recruiting now

2 registrations that name bifidobacterium breve as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.

Trial Finder Read from ClinicalTrials.gov Oct 20, 2026 The Bifidobacterium breve supplement page

Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.

Filter 2 registrations

Status

Location

All 2 registrations

Not yet recruitingNCT06850714

Evaluation of Bifidobacterium Breve PRL2020 in Preventing Antibiotic-Associated Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid

No phase
Liaquat University of Medical & Health Sciences
About 800 people
Starts Feb 23, 2025 (estimated)

In plain words A study of bifidobacterium breve in people 3 to 12, run by Liaquat University of Medical & Health Sciences. It plans to enroll about 800 people at 1 site, none in the US.

Who it lists and where

Who the trial lists, as registered

Lists people 3 to 12. Conditions: Antibiotic Side Effect.

Age 3 to 12 years
Requiring antibiotic therapy with Amoxicillin or Amoxicillin/Clavulanic Acid
Ability to comply with the study protocol (parents/caregivers must complete symptom diaries)

The exclusion criteria are on the listing.

What it tests, as registered

Bifidobacterium breve PRL2020 (Brevicillin®); Amoxicillin or Amoxicillin/Clavulanic Acid

Registered summary

This study aims to evaluate the efficacy and safety of the probiotic Bifidobacterium breve PRL2020 in preventing gastrointestinal and extra-intestinal side effects caused by Amoxicillin or Amoxicillin/Clavulanic Acid in pediatric patients. The study will compare a treatment group receiving the probiotic alongside antibiotics with a control group receiving antibiotics alone. The primary focus is on reducing antibiotic-induced intestinal discomfort through microbiota modulation.

Where, as registered

No US site; Italy (1).

Not yet recruitingNCT07466511

Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis

No phase
Second Affiliated Hospital of Wenzhou Medical University
About 100 people
Starts Jan 1, 2027 (estimated)

In plain words A study of bifidobacterium breve in people 6 to 15, run by Second Affiliated Hospital of Wenzhou Medical University. It plans to enroll about 100 people at 1 site, none in the US.

Who it lists and where

Who the trial lists, as registered

Lists people 6 to 15. Conditions: Idiopathic Scoliosis.

Age 6 to 15 years

The exclusion criteria are on the listing.

What it tests, as registered

Bifidobacterium breve; Lifestyle Education

Registered summary

Researchers hypothesized that Bifidobacterium breve Supplement could reduce the progression rate of idiopathic scoliosis in children and potentially prevent the occurrence of new cases of scoliosis.

Where, as registered

No US site; China (1).

ClinicalTrials.gov lists 12 open registrations for this search, including ones where bifidobacterium breve is not a study arm or that are past the 2 we keep. Search them on ClinicalTrials.gov (opens in new tab).

Also on Kymata

Supplement brands we have checkedEvery supplement brand we have reviewed.